We next sought to define whether the C/EBPα mutation would alter the hematopoietic differentiation phenotype observed in cells containing mutations in SRSF2 and RUNX1, and thus serve as a model system to study disease progression for this type of MDS. This evidence concerns the gene CEBPA and myelodysplastic syndrome.